State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary.
Saved in:
| Title: | State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary. |
|---|---|
| Authors: | Epps QJ; Florida Agricultural and Mechanical University College of Pharmacy and Pharmaceutical Sciences, Jacksonville, Florida, USA., Epps KL; Department of Pharmacy, The Mayo Clinic, Jacksonville, Florida, USA., Young DC; Department of Pharmacotherapy, L.S. Skaggs Pharmacy Institute, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.; Department of Pharmacy, University of Utah Adult Cystic Fibrosis Center, Salt Lake City, Utah, USA., Zobell JT; Department of Pharmacy, Intermountain Primary Children's Hospital, Salt Lake City, Utah, USA.; Department of Pharmacy, Primary Children's Cystic Fibrosis Center, Salt Lake City, Utah, USA. |
| Source: | Pediatric pulmonology [Pediatr Pulmonol] 2021 Jul; Vol. 56 (7), pp. 1825-1837. Date of Electronic Publication: 2021 Mar 15. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8510590 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-0496 (Electronic) Linking ISSN: 10990496 NLM ISO Abbreviation: Pediatr Pulmonol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
